210 related articles for article (PubMed ID: 36343656)
1. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial.
Guadagnolo BA; Bassett RL; Mitra D; Farooqi A; Hempel C; Dorber C; Willis T; Wang WL; Ratan R; Somaiah N; Benjamin RS; Torres KE; Hunt KK; Scally CP; Keung EZ; Satcher RL; Bird JE; Lin PP; Moon BS; Lewis VO; Roland CL; Bishop AJ
Lancet Oncol; 2022 Dec; 23(12):1547-1557. PubMed ID: 36343656
[TBL] [Abstract][Full Text] [Related]
2. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
[TBL] [Abstract][Full Text] [Related]
3. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
4. Prospective phase II trial of preoperative hypofractionated proton therapy for extremity and truncal soft tissue sarcoma: the PRONTO study rationale and design.
Gogineni E; Chen H; Hu C; Boudadi K; Engle J; Levine A; Deville C
Radiat Oncol; 2024 May; 19(1):56. PubMed ID: 38745333
[TBL] [Abstract][Full Text] [Related]
5. Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review.
Roohani S; Ehret F; Kobus M; Flörcken A; Märdian S; Striefler JK; Rau D; Öllinger R; Jarosch A; Budach V; Kaul D
Radiat Oncol; 2022 Sep; 17(1):159. PubMed ID: 36104789
[TBL] [Abstract][Full Text] [Related]
6. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
7. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
8. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
Mutter RW; Giri S; Fruth BF; Remmes NB; Boughey JC; Harless CA; Ruddy KJ; McGee LA; Afzal A; Gao RW; Shumway DA; Vern-Gross TZ; Villarraga HR; Kenison SL; Kang Y; Wong WW; Stish BJ; Merrell KW; Yan ES; Park SS; Corbin KS; Vargas CE
Lancet Oncol; 2023 Oct; 24(10):1083-1093. PubMed ID: 37696281
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Radiosurgery for Soft Tissue Sarcoma.
Kubicek GJ; LaCouture T; Kaden M; Kim TW; Lerman N; Khrizman P; Patel A; Xu Q; Lackman R
Am J Clin Oncol; 2018 Jan; 41(1):86-89. PubMed ID: 26535989
[TBL] [Abstract][Full Text] [Related]
12. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.
Bonvalot S; Rutkowski PL; Thariat J; Carrère S; Ducassou A; Sunyach MP; Agoston P; Hong A; Mervoyer A; Rastrelli M; Moreno V; Li RK; Tiangco B; Herraez AC; Gronchi A; Mangel L; Sy-Ortin T; Hohenberger P; de Baère T; Le Cesne A; Helfre S; Saada-Bouzid E; Borkowska A; Anghel R; Co A; Gebhart M; Kantor G; Montero A; Loong HH; Vergés R; Lapeire L; Dema S; Kacso G; Austen L; Moureau-Zabotto L; Servois V; Wardelmann E; Terrier P; Lazar AJ; Bovée JVMG; Le Péchoux C; Papai Z
Lancet Oncol; 2019 Aug; 20(8):1148-1159. PubMed ID: 31296491
[TBL] [Abstract][Full Text] [Related]
13. Early outcomes of ultra-hypofractionated preoperative radiation therapy for soft tissue sarcoma followed by immediate surgical resection.
Mayo ZS; Parsai S; Asha W; Dinh M; Mesko N; Nystrom L; Shah CS; Scott JG; Campbell SR
Radiother Oncol; 2023 Mar; 180():109439. PubMed ID: 36481382
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
15. A systematic overview of radiation therapy effects in soft tissue sarcomas.
Strander H; Turesson I; Cavallin-Ståhl E
Acta Oncol; 2003; 42(5-6):516-31. PubMed ID: 14596510
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC; Ostler P; van der Voet H; Chu W; Loblaw A; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Armstrong J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Duffton A; Brand DH; Henderson D; Morrison K; Brown S; Pugh J; Burnett S; Mahmud M; Hinder V; Naismith O; Hall E; van As N;
Lancet Oncol; 2022 Oct; 23(10):1308-1320. PubMed ID: 36113498
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
18. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
Weiss AR; Chen YL; Scharschmidt TJ; Chi YY; Tian J; Black JO; Davis JL; Fanburg-Smith JC; Zambrano E; Anderson J; Arens R; Binitie O; Choy E; Davis JW; Hayes-Jordan A; Kao SC; Kayton ML; Kessel S; Lim R; Meyer WH; Million L; Okuno SH; Ostrenga A; Parisi MT; Pryma DA; Randall RL; Rosen MA; Schlapkohl M; Shulkin BL; Smith EA; Sorger JI; Terezakis S; Hawkins DS; Spunt SL; Wang D
Lancet Oncol; 2020 Aug; 21(8):1110-1122. PubMed ID: 32702309
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
[TBL] [Abstract][Full Text] [Related]
20. Are We Ready for Life in the Fast Lane? A Critical Review of Preoperative Hypofractionated Radiotherapy for Localized Soft Tissue Sarcoma.
Guadagnolo BA; Baldini EH
Semin Radiat Oncol; 2024 Apr; 34(2):180-194. PubMed ID: 38508783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
